These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 8303978)
1. [Effect of human recombinant erythropoietin (rhuEPO) on platelet phospholipids in chronically hemodialysed]. Krawczyk W; Dmoszyńska A; Ledwozyw A; Soroka-Wojtaszko M Acta Haematol Pol; 1993; 24(4):327-31. PubMed ID: 8303978 [TBL] [Abstract][Full Text] [Related]
2. Human erythropoietin improves the blood platelet phospholipid composition in chronically hemodialyzed patients. Krawczyk W; Dmoszyńska A; Marczewski K; Ledwozyw A Exp Nephrol; 1995; 3(4):265-6. PubMed ID: 8590040 [TBL] [Abstract][Full Text] [Related]
3. [The influence of recombinant human erythropoietin on platelet phospholipid fatty acid composition in patients on long term hemodialysis]. Krawczyk W; Dmoszyńska A; Ledwozyw A Pol Merkur Lekarski; 1996 Dec; 1(6):394-7. PubMed ID: 9273229 [TBL] [Abstract][Full Text] [Related]
4. Enhanced platelet reactivity with erythropoietin but not following transfusion in dialysis patients. Roger SD; Piper J; Tucker B; Raine AE; Baker LR; Kovacs IB Nephrol Dial Transplant; 1993; 8(3):213-7. PubMed ID: 8385286 [TBL] [Abstract][Full Text] [Related]
5. [The effect of human recombinant erythropoietin on levels of plasma phospholipids in patients chronically treated with hemodialysis]. Krawczyk W; Dmoszyńska A; Ledwozyw A; Marczewski K Pol Arch Med Wewn; 1995 Jul; 94(1):21-5. PubMed ID: 8524695 [TBL] [Abstract][Full Text] [Related]
6. Expression of fibrinogen receptors and GPIIb molecules on uraemic platelets: effect of recombinant human erythropoietin therapy. Krzesłowska J; Rysz J; Cierniewski CS; Luciak M Nephrol Dial Transplant; 1995; 10(5):653-6. PubMed ID: 7566578 [TBL] [Abstract][Full Text] [Related]
7. [The effect of human recombinant erythropoietin on distribution of membrane phospholipids in blood platelets of patients with uremia treated with repeated hemodialysis]. Krawczyk W; Ledwozyw A; Dmoszyńska A; Krzywicka A; Rózyc P Pol Arch Med Wewn; 1997 Feb; 97(2):120-5. PubMed ID: 9312760 [TBL] [Abstract][Full Text] [Related]
8. Erythropoietin improves signaling through tyrosine phosphorylation in platelets from uremic patients. Diaz-Ricart M; Etebanell E; Cases A; López-Pedret J; Castillo R; Ordinas A; Escolar G Thromb Haemost; 1999 Oct; 82(4):1312-7. PubMed ID: 10544920 [TBL] [Abstract][Full Text] [Related]
9. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients. Pawlak K; Pawlak D; Mysliwiec M Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326 [TBL] [Abstract][Full Text] [Related]
11. Recombinant human erythropoietin increases blood pressure, platelet aggregability and platelet free calcium mobilisation in uraemic children: a possible link? Van Geet C; Van Damme-Lombaerts R; Vanrusselt M; de Mol A; Proesmans W; Vermylen J Thromb Haemost; 1990 Aug; 64(1):7-10. PubMed ID: 2274929 [TBL] [Abstract][Full Text] [Related]
12. [Platelet aggregation during the recombinant human erythropoietin (rHuEPO) treatment of patients with uremia]. Mazerska M; Pawlak K; Azzadin A; Małyszko J; Małyszko J; Myśliwiec M; Buczko W Pol Arch Med Wewn; 1992 Oct; 88(4):230-7. PubMed ID: 1488323 [TBL] [Abstract][Full Text] [Related]
13. Selective modifications of the phospholipid fatty acid composition in human platelet membranes using nonspecific and specific lipid transfer proteins. Bayon Y; Croset M; Guerbette F; Daveloose D; Chirouze V; Viret J; Kader JC; Lagarde M Anal Biochem; 1995 Sep; 230(1):75-84. PubMed ID: 8585633 [TBL] [Abstract][Full Text] [Related]
14. Influence of long-term recombinant human erythropoietin (rHuEpo) therapy on plasma leptin and neuropeptide Y concentration in haemodialysed uraemic patients. Kokot F; Wiecek A; Mesjasz J; Adamczak M; Spiechowicz U Nephrol Dial Transplant; 1998 May; 13(5):1200-5. PubMed ID: 9623554 [TBL] [Abstract][Full Text] [Related]
15. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients. Pawlak K; Pawlak D; Mysliwiec M Thromb Res; 2007; 120(6):797-803. PubMed ID: 17391740 [TBL] [Abstract][Full Text] [Related]
16. Recombinant human erythropoietin shortens the uraemic bleeding time without causing intravascular haemostatic activation. Gordge MP; Leaker B; Patel A; Oviasu E; Cameron JS; Neild GH Thromb Res; 1990 Jan; 57(2):171-82. PubMed ID: 2315882 [TBL] [Abstract][Full Text] [Related]
18. [Reticulocyte response after immediate withdrawal of recombinant human erythropoietin in chronic hemodialysis patients]. Caramelo C; Soto C; Neira F; López MD; Jiménez S; Albalate M; de Oña R; Llamas P; Deudero JJ Nefrologia; 2004; 24(4):351-6. PubMed ID: 15455495 [TBL] [Abstract][Full Text] [Related]
19. Effects of recombinant human erythropoietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: results of a double-blind, placebo-controlled randomized trial. Tang YD; Rinder HM; Katz SD Am Heart J; 2007 Sep; 154(3):494.e1-7. PubMed ID: 17719296 [TBL] [Abstract][Full Text] [Related]
20. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients. Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]